TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03100942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanraplenib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanraplenib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgotinib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib placebo
Description: 1 x tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tirabrutinib placebo
Description: 1 x tablet administered orally once daily
Study: NCT03856086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline questionnaire
Description: Baseline questionnaire on the day of the patient's surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline questionnaire
Description: Baseline questionnaire on the day of the patient's surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCCN Problem List
Description: NCCN Distress Thermometer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCCN Problem List
Description: NCCN Distress Thermometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT-GP
Description: Greater overall quality of life

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FACT-GP
Description: Greater overall quality of life
Study: NCT00271024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Naltrexone)
Description: Sugar pill manufactured to mimic Naltrexone tablet
Study: NCT02709629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized and adaptive computerized cognitive training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Study: NCT04651920

Intervention type: GENETIC
Intervention: Evaluation of homologous recombination deficiency score
Description: Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)

Intervention type: GENETIC
Intervention: Evaluation of homologous recombination deficiency score
Description: Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
Study: NCT04271072

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04674709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleander 4X - single
Description: Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleander 4X - single
Description: Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleander 4X - double
Description: Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleander 4X - double
Description: Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleander 4X - quadruple
Description: Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oleander 4X - quadruple
Description: Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
Study: NCT01163942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Yes/no addition of G-CSF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early retreatment with ATG
Description: Yes/no early retreatment with ATG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early retreatment with ATG
Description: Yes/no early retreatment with ATG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early retreatment with ATG
Description: Yes/no early retreatment with ATG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early retreatment with ATG
Description: Yes/no early retreatment with ATG
Study: NCT03960736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESP block (Group A)
Description: US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA group (Group B)
Description: Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
Study: NCT03599765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive routine therapy
Study: NCT00630370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets, TID, orally, 58 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg ATI 7505
Description: 1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
Study: NCT03599765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive routine therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Receive LCT
Study: NCT00712283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neramexane mesylate
Description: tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neramexane mesylate
Description: tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neramexane mesylate
Description: tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neramexane mesylate
Description: tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
Study: NCT00864357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
Description: A: Experimental SSubjects received Actavis formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBONOX® tablets, single dose
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
Study: NCT00630370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg ATI 7505
Description: 1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ATI 7505
Description: 2 ATI 40mg tablets, TID, orally, 58 days
Study: NCT03720353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS2094AH and SAS2094BH
Description: SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS2094AL and SAS2094BL
Description: SAS2094AL and SAS2094BL for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 10 days. Capsules will mimic active treatments.
Study: NCT01024335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable naltrexone and dronabinol
Description: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone and placebo
Description: Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
Study: NCT03144921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducational skills training intervention
Description: This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducational skills training intervention
Description: This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
Study: NCT00002561

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: 10 units/m2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin sulfate
Description: 10 units/m2
Study: NCT04339062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab: via IV, flat predetermined dosage every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab: via IV, flat predetermined dosage every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
Study: NCT04503369

Intervention type: BEHAVIORAL
Intervention: Non-technical skills
Description: Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team.
Study: NCT00149357

Intervention type: OTHER
Intervention: Thrombophilia Testing
Description: TP testing in Group 1 and 3 only
Study: NCT02853292

Intervention type: BIOLOGICAL
Intervention: urine collection
Study: NCT00685295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl rapid dissolving tablet 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: lansoprazole 15mg rapidly dissolving tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone 5/325 mg tablet
Study: NCT04085250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy
Description: The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy concurrent with radiotherapy
Description: Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy concurrent with radiotherapy
Description: Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiation technique was used to deliver a definitive radiation dose

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Hypofractionated radiation technique was used to deliver a definitive radiation dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
Study: NCT03859011

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Physical therapy, oral medications and topical ointments pre the discretion of the primary physician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
Study: NCT03088683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nathanson Retractor
Description: Liver will be retracted with Nathanson retractor
Study: NCT03856086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HADS
Description: Lower anxiety and depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HADS
Description: Lower anxiety and depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CSS-CG
Description: web-based CSS-CG
Study: NCT00638326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: 150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel plus placebo
Description: 75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
Study: NCT03088683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveel Retractor
Description: Liver will be retracted with Reveel retractor
Study: NCT00002561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: 375mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: 375mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 25mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: 25mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Description: 6mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Description: 6mg/m2

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 35Gy in 20 fractions (daily)
Study: NCT04521816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Intensive Management
Description: Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues
Study: NCT00469378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: firategrast
Description: 900 (females) or 1200 (males) mg twice daily for 24 weeks
Study: NCT00712166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI 75 mg three times daily (TID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo three times daily (TID)
Study: NCT02661646

Intervention type: DEVICE
Intervention: Advanced Pneumatic Compression Device
Description: Advanced Pneumatic Compression Device
Study: NCT00556062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal split influenza vaccine
Description: 0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal split influenza vaccine
Description: 0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal split influenza vaccine
Description: 0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: seasonal split influenza vaccine
Description: 0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
Study: NCT03947112

Intervention type: BEHAVIORAL
Intervention: Physical activity registration
Description: At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
Study: NCT01264718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Mentors
Description: After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
Study: NCT02908464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumosity
Description: A neurocognitive training program designed to enhance cognitive abilities
Study: NCT03102242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.